Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Long-term outcomes and complications in cancer patients who have recovered from...

Dr David Pinato - Imperial College London, London, UK

Long-term outcomes and complications in cancer patients who have recovered from COVID-19 ( Dr David Pinato - Imperial College London, London, UK )

6 months trastuzumab non-inferior to 12 months for HER2 positive early breast...

Prof Helena Earl - University of Cambridge, Cambridge, United Kingdom

6 months trastuzumab non-inferior to 12 months for HER2 positive early breast cancer ( Prof Helena Earl - University of Cambridge, Cambridge, United Kingdom )

Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or...

Prof Thomas Powles - Queen Mary University of London, London, UK

Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or locally advanced urothelial carcinoma (mUC) and FGFRa ( Prof Thomas Powles - Queen Mary University of London, London, UK )

ESMO President: What to watch for at ESMO 2021

Prof Solange Peters - ESMO President

ESMO President: What to watch for at ESMO 2021 ( Prof Solange Peters - ESMO President )

Nivolumab plus ipilimumab shows benefit over chemo for unresectable malignant...

Prof Solange Peters - Lausanne University Hospital, Lausanne, Switzerland

Nivolumab plus ipilimumab shows benefit over chemo for unresectable malignant pleural mesothelioma ( Prof Solange Peters - Lausanne University Hospital, Lausanne, Switzerland )

OncoAlert and ecancer - ESMO 2021 preview

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer - ESMO 2021 preview ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and...

Dr Enrique Ocio - Marqués de Valdecilla University Hospital, Santander, Spain

Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and dexamethasone combined therapy for NDMM ( Dr Enrique Ocio - Marqués de Valdecilla University Hospital, Santander, Spain )

Multidisciplinary management of ovarian germ cell tumours - a single...

Dr Sandip Ganguly - Tata Medical Center, Kolkata, India

Multidisciplinary management of ovarian germ cell tumours - a single institutional study from India ( Dr Sandip Ganguly - Tata Medical Center, Kolkata, India )

Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or...

Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA

Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in RRMM patients ( Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA )

Should every transplant eligible NDMM patient receive a transplant?

Prof Morie Gertz - Mayo Clinic, Rochester, USA

Should every transplant eligible NDMM patient receive a transplant? ( Prof Morie Gertz - Mayo Clinic, Rochester, USA )

Suboptimal humoral immune response to COVID-19 vaccination in myeloma patients

Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City...

Suboptimal humoral immune response to COVID-19 vaccination in myeloma patients ( Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, USA )

Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA...

Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City...

$Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy ( Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, USA )$

More from ecancer